NCT01991587View on ClinicalTrials.gov

Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 8, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Virus DiseasesRNA Virus InfectionsRespiratory Tract DiseasesRespiratory Tract Infections
Interventions
BIOLOGICAL

Low dose of quadrivalent VLP vaccine

A single low dose of quadrivalent VLP vaccine

BIOLOGICAL

Medium dose of quadrivalent VLP vaccine

A single medium dose of quadrivalent VLP vaccine

BIOLOGICAL

High dose of quadrivalent VLP vaccine

A single high dose of quadrivalent VLP vaccine

BIOLOGICAL

Placebo

A single dose of placebo

Trial Locations (1)

33143

Miami Research Associates, Miami

Sponsors

Lead Sponsor

Medicago
All Listed Sponsors
lead

Medicago

INDUSTRY

NCT01991587 - Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults | Biotech Hunter | Biotech Hunter